GLUE

MONTE ROSA THERAPEUTICS INC

GLUE·61225M102·US·Common Stock·Healthcare - Biotechnology-Activist

GLUE (MONTE ROSA THERAPEUTICS INC) is held by 105 institutional investors as of Q2 2026. Largest holders: BlackRock, Inc. ($165.6M), BAKER BROS. ADVISORS LP ($105.2M), STATE STREET CORP ($90.3M). Net institutional sentiment: Mixed.

105
Holders
(7 Elite)
$952.3M
Total Value
61% (110)
Consensus
67 buying - 43 selling
13F: Insider & Congress: Updated regularly
GLUE

Smart Money Verdict

View all
Loading verdict
Held by 105 funds
7 elite

Who's Trading

Source dates: Price Aug 21, 2026 · Insiders Jun 30, 2026 · Activists Aug 14, 2026 · Congress none

ActivistMOMontanova Capital, LLC4.2%Aug 14, 2026
ActivistVPVestal Point Capital, LP5.4%Aug 14, 2026
ActivistT. Rowe Price Associates, Inc.T. Rowe Price Associates, Inc.10.5%Jul 8, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
6.8M(+21.4%)$165.6M0.0%+11.50%
36
Unchanged
4.3M$105.2M0.5%+136.88%
0
Increased
3.7M(+11.3%)$90.3M0.0%-6.10%
33
Increased
3.4M(+10.1%)$82.6M0.0%-22.83%
33
Increased
1.9M(+21.0%)$45.1M0.0%+2.63%
35
Decreased
1.6M(-42.2%)$39.3M0.0%-3.61%
0
Increased
1.6M(+11.2%)$38.6M0.0%-9.32%
32
Increased
1.2M(+13.1%)$28.5M0.0%+12.17%
32
Decreased
998,253(-0.3%)$24.2M0.0%-12.60%
0
Increased
962,884(+1192.5%)$23.3M0.1%-39.71%
46
Decreased
934,414(-8.8%)$22.6M0.0%+102.15%
0
Increased
791,932(+53.5%)$19.2M0.0%-28.98%
40
Increased
789,545(+15.4%)$19.1M0.0%+37.11%
33
Decreased
652,087(-21.1%)$15.8M0.0%+55.73%
0
New
647,796$15.7M0.0%-40.91%
39
Increased
616,310(+12.7%)$14.9M0.0%+5.44%
32
Decreased
520,648(-20.9%)$12.6M0.0%+152.49%
0
Increased
505,500(+24.2%)$12.2M0.0%-25.42%
34
Increased
450,000(+80.0%)$10.9M0.0%-31.03%
43
Increased
383,335(+964.9%)$9.3M0.0%-38.96%
45

Showing 1-20 of 115

1 / 6
GLUEGLUEMONTE ROSA THERAPEUTICS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used